Titan Pharmaceuticals Inc.

0.8120-0.0305-3.62%Vol 25.94K1Y Perf -41.49%
Nov 30th, 2022 15:52 DELAYED
BID0.8120 ASK0.8350
Open0.8193 Previous Close0.8425
Pre-Market- After-Market0.82
 - -  0.01 0.99%
Target Price
7.00 
Analyst Rating
Hold 3.00
Potential %
762.07 
Finscreener Ranking
+     37.61
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     40.14
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     42.05
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
37.28 
Earnings Rating
Neutral
Market Cap11.88M 
Earnings Date
5th Dec 2022
Alpha-0.07 Standard Deviation0.23
Beta0.44 

Today's Price Range

0.81000.8400

52W Range

0.34961.59

5 Year PE Ratio Range

-0.200025.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-9.36%
1 Month
-18.15%
3 Months
-38.95%
6 Months
91.69%
1 Year
-41.49%
3 Years
-82.19%
5 Years
-99.71%
10 Years
-99.92%

TickerPriceChg.Chg.%
TTNP0.8120-0.0305-3.62
AAPL148.036.86004.86
GOOG101.456.01006.30
MSFT255.1414.81006.16
XOM111.340.80000.72
WFC47.950.38000.80
JNJ178.001.91001.08
FB196.640.99000.51
GE85.970.31000.36
JPM138.181.62001.19
 
ProfitabilityValueIndustryS&P 500US Markets
100.00
-784.00
-768.10
-1 825.80
-
RevenueValueIndustryS&P 500US Markets
481.00K
0.03
-33.27
-5.08
Earnings HistoryEstimateReportedSurprise %
Q03 2021--0.19-
Q02 2021--0.24-
Q01 2021--0.28-
Q03 2020-1.20-1.50-25.00
Q02 2020-0.90-1.50-66.67
Q01 2020--1.80-
Q04 2019--2.40-
Q03 2019-6.61-5.4118.15
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.010.00-
12/2020 QR-0.010.00-
12/2020 FY-0.150.00-
12/2021 FY-0.130.00-
Next Report Date5th Dec 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume25.94K
Shares Outstanding14.63K
Shares Float14.57M
Trades Count139
Dollar Volume21.33K
Avg. Volume26.46K
Avg. Weekly Volume26.73K
Avg. Monthly Volume20.61K
Avg. Quarterly Volume32.06K

Titan Pharmaceuticals Inc. (NASDAQ: TTNP) stock closed at 0.812 per share at the end of the most recent trading day (a -3.62% change compared to the prior day closing price) with a volume of 25.94K shares and market capitalization of 11.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 21 people. Titan Pharmaceuticals Inc. CEO is Marc Rubin.

The one-year performance of Titan Pharmaceuticals Inc. stock is -41.49%, while year-to-date (YTD) performance is -20.39%. TTNP stock has a five-year performance of -99.71%. Its 52-week range is between 0.3496 and 1.59, which gives TTNP stock a 52-week price range ratio of 37.28%

Titan Pharmaceuticals Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 3.67, a price-to-sale (PS) ratio of 27.00, a price to cashflow ratio of 7.90, a PEG ratio of 2.32, a ROA of -141.00%, a ROC of -175.71% and a ROE of -205.65%. The company’s profit margin is -%, its EBITDA margin is -768.10%, and its revenue ttm is $481.00 Thousand , which makes it $0.03 revenue per share.

Of the last four earnings reports from Titan Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Titan Pharmaceuticals Inc.’s next earnings report date is 05th Dec 2022.

The consensus rating of Wall Street analysts for Titan Pharmaceuticals Inc. is Hold (3), with a target price of $7, which is +762.07% compared to the current price. The earnings rating for Titan Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Titan Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Titan Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.57, ATR14 : 0.07, CCI20 : -167.96, Chaikin Money Flow : -0.13, MACD : -0.04, Money Flow Index : 35.60, ROC : -4.07, RSI : 31.12, STOCH (14,3) : 13.24, STOCH RSI : 0.00, UO : 42.50, Williams %R : -86.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Titan Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products. The company product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants.

CEO: Marc Rubin

Telephone: +1 650 244-4990

Address: 400 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 21

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

Bearish Bullish

54%46%


News

Stocktwits